Regarding discontinuation, Aldrich et al. [20] found a significant association between the discontinuation of (es)citalopram in youth with anxiety and/or depression and CYP2C19 PM and IM status, which is partly in line with our study, where the children and adolescents who were using (es)citalopram with a CYP2C19 IM phenotype had a slightly increased, but statistically insignificant, risk for discontinuation. Here, CYP2C19 is linked to depressive symptom measurement.